A Randomized Phase 2 Study to Evaluate Three Treatment Regimens of SHAPE, a Histone Deacetylase Inhibitor, in Patients With Stage IA, IB or IIA Cutaneous T-Cell Lymphoma
Phase of Trial: Phase II
Latest Information Update: 13 Oct 2017
At a glance
- Drugs Remetinostat (Primary)
- Indications Cutaneous T cell lymphoma
- Focus Therapeutic Use
- Sponsors TetraLogic Pharmaceuticals
- 13 Oct 2017 According to a Medivir AB media release, data were presented as an abstract at the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force meeting October 2017.
- 13 Oct 2017 Results presented in a Medivir AB media release.
- 07 Apr 2017 According to a Medivir AB media release, company is planning present full data at scientific meetings in the second half of 2017. Based on the data from this trial company is planning to initiate discussions with regulatory authorities with the aim of initiating a phase III study (see profile 278464) later in 2017.